|
Real-time Estimate
Cboe BZX
18:09:32 13/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 31.30 USD | -0.40% |
|
+4.84% | +1.54% |
| 08-12 | BNP Paribas Initiates Genmab at Outperform, With $40 Price Target | MT |
| 08-12 | Nordic stocks in North America: AstraZeneca fell 1.0% | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 70.1B | |||||
| 54.93B | |||||
| 28.89B | - | ||||
| 23.9B | |||||
| 23.3B | - |
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Charts Genmab A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
